US companies hit hardest by fake medicines: EUIPO, OECD
Companies registered in the US are hit hardest by the trade in counterfeit medicines, which in 2016 reached $4.4 billion, according to a report from the European Union Intellectual Property Office (EUIPO).
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
1 May 2020 Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.
22 April 2020 The COVID-19 pandemic is heightening the dangers posed by the global trade in counterfeit pharmaceutical products, according to the OECD and EUIPO.